580 results on '"Fumery M"'
Search Results
2. Severe erosive gingivostomatitis in a patient treated by vedolizumab
3. Maladie chronique inflammatoire de l’intestin et grossesse : de la conception à la naissance
4. P927 Long-term outcomes of risankizumab in Crohn’s disease: a multicenter GETAID Study
5. P386 Persistence of bowel urgency despite clinical remission after induction therapy is associated with unfavorable long-term outcomes in patients with ulcerative colitis: results from the multicenter UC-RGENCY study
6. DOP05 Bowel damage and its correlation with the disability index in patients with recently diagnosed Crohn´s Disease
7. P943 Real world Effectiveness and safety of tofacitinib in patients with Ulcerative Colitis: 6 months follow-up of the French TOFAST study
8. P408 Complete endoscopic healing, the future therapeutic target in Crohn's disease? Results of a prospective multicenter study
9. P1151 Incidence and risk factors of thromboembolic events in Pediatric-Onset Inflammatory Bowel Disease: a population-based study
10. P857 Effectiveness and safety of subcutaneous infliximab in perianal Crohn's disease: a multicentre cohort study
11. P275 Fecal calprotectin, intestinal ultrasound, and their combination for the diagnosis of Crohn’s disease
12. P1071 Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID
13. P322 Compared Efficacy of Second-Line Treatments for Ulcerative Colitis After Failure of Vedolizumab in First-Line Treatment: A Retrospective Multicenter Study
14. P360 Prevalence and risk factors for fatigue in patients with inflammatory bowel disease and endoscopic healing
15. DOP79 Promising efficacy of biologicals and small molecules for microscopic colitis: results from a large real-life multicenter cohort
16. P1015 Subcutaneous infliximab effectively manages clinical outcomes of Inflammatory Bowel Disease independently of various confounding factors
17. P679 Anti-TNF de-escalation following a treat-to-target strategy with golimumab therapy intensification to reach continuous clinical response in ulcerative colitis: the In-Target GETAID trial
18. P318 Performance of rectosigmoidoscopy and rectoscopy to assess endoscopic and histological healing in ulcerative colitis
19. DOP23 The role of histology for the prediction of clinical relapse in Crohn’s Disease: A substudy of the STORI cohort
20. P733 Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases treated with intensified doses: the REMSWITCH-LT study
21. P226 Disability in Crohn’s Disease Patients at diagnosis: Findings from the CROCO (Crohn´s Disease Cohort) study
22. P1122 Comorbidities Associated with Pediatric Onset Inflammatory Bowel Diseases: A Population-Based Study
23. P1125 Incidence and Neoplastic Risk Associated with Colonic Stricture in Pediatric-Onset Crohn's Disease: A Population-based Study
24. P231 Impact of the depth of mucosal healing on the burden of ulcerative colitis : a cross-sectional study
25. P712 Effectiveness of switching from intravenous to subcutaneous infliximab in Inflammatory Bowel Disease patients: A combined analysis of real-world evidence
26. Long‐term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH‐LT study.
27. Serum procalcitonin correlates with colonoscopy findings and can guide therapeutic decisions in postoperative ischemic colitis
28. Disease course of Crohn's disease during the first ten years following diagnosis in a prospective European population-based inception cohort - the Epi-IBD cohort
29. Disease course of Ulcerative Colitis during the first ten years following diagnosis in a prospective European population-based inception cohort - the Epi-IBD cohort
30. Impact of Extra-Intestinal Manifestations at Diagnosis on Disease Outcome in Pediatric- and Elderly-Onset Crohn′s Disease: A French Population-Based Study
31. P435 Real-world comparison of effectiveness between ustekinumab and a second anti-TNF agent in patients with symptomatic stenosing Crohn's disease after failure of a first anti-TNF agent: results of the USTEKNOSIS study
32. P450 Real life Effectiveness and safety of an induction treatment with tofacitinib in patients with Ulcerative Colitis: First results of the French TOFAST cohort
33. P443 Risk of incident Cancer in Patients with Inflammatory Bowel Disease with Prior Breast Cancer: a Multicentre Cohort Study
34. P338 Transmural healing is not associated with less disability than complete endoscopic mucosal healing: a prospective study in a patient with Crohn's disease
35. P299 Disability in newly diagnosed patients with Crohn′s Disease: initial results from the prospective CROCO (Crohn′s Disease Cohort) Study
36. P130 Intestinal ultrasound combined to fecal calprotectin is effective to predict endoscopic mucosal healing in ulcerative colitis: a cross-sectional study
37. DOP45 Predicting late responders to filgotinib in patients with moderately to severely active Ulcerative Colitis: A post hoc analysis of SELECTION and SELECTIONLTE
38. P155 Natural history of anal stricture in pediatric-onset Crohn’s disease: a two-decades population-based study
39. P876 Disease course of Inflammatory Bowel Disease Unclassified in adult patients : a population-based study (1988-2014)
40. P579 Real-world comparison of effectiveness between tofacitinib and ustekinumab in patients with ulcerative colitis exposed to at least one anti-TNF agent: results from the TORUS study
41. P303 Ultrasound is effective to identify mucosal healing in Crohn's disease patients : results of a cross-sectional study
42. Long‐term efficacy and safety of ustekinumab in 122 refractory Crohnʼs disease patients: a multicentre experience
43. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab
44. Impact of vedolizumab therapy on extra‐intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV‐IBD cohort
45. DOP029 Treatment and long-term outcomes of paediatric patients with penetrating Crohn’s disease
46. DOP019 Immunomodulators reduce the risk of surgery and hospitalisation in Crohn’s disease in a prospective European population-based inception cohort: the Epi-IBD cohort
47. OP009 A combination of clinical, serological, and genetic factors predicts complicated disease course in paediatric-onset Crohn’s disease: results from a population-based study
48. Systematic review with network meta‐analysis: first‐ and second‐line pharmacotherapy for moderate‐severe ulcerative colitis
49. Efficacy and safety of golimumab in Crohnʼs disease: a French national retrospective study
50. Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.